semaglutide patent expiration 2031 Off-patent in 2026: the next revolution in anti-obesity medications Semaglutide's patent expires today. What

The oral semaglutide formulation addresses injection-averse patient populations, capturing share in primary care settings where oral administration reduces treatment initiation barriers [2]

The identification of the pleiotropic SNP PMSnpB394 , associated with 14 vigor and longevity-related traits, highlights genomic regions of major effect influencing seed performance and viability

P38 MAPK, p38 Mitogen-Activated Protein Kinase

Tirzepatide, semaglutide, liraglutide, and, to a lesser extent, naltrexonebupropion provided significant improvement in glycemic parameters and variable rates of type 2 diabetes remission 6 (Table 1)